🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

18,91 USD

Máx. histórico

48,47

1806 días

Caída desde máximo

-60,99%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+5,94%

Cierre anterior

17,85

Rango de hoy

18,05 – 18,98

Volumen hoy

1.935.563

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,63%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 21 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
08/08/2018 11,26 11,58 11,26 11,52 +2,49% 2,84% 47.300
07/08/2018 10,98 11,47 10,80 11,24 +3,31% 6,10% 66.700
06/08/2018 10,99 11,15 10,86 10,88 -1,09% 2,64% 35.500
03/08/2018 11,30 11,30 10,90 11,00 -2,14% 3,54% 56.200
02/08/2018 11,47 11,87 11,20 11,24 -2,52% 5,84% 48.000
01/08/2018 11,71 11,96 11,27 11,53 -1,45% 5,85% 90.600
31/07/2018 11,60 12,00 11,24 11,70 +1,30% 6,59% 57.000
30/07/2018 11,35 11,74 11,31 11,55 +2,03% 3,80% 48.900
27/07/2018 11,68 12,01 11,31 11,32 -3,00% 5,99% 74.600
26/07/2018 11,44 11,78 11,31 11,67 +2,01% 4,10% 24.000
25/07/2018 11,59 11,74 11,07 11,44 -0,87% 5,75% 47.200
24/07/2018 11,65 11,76 11,39 11,54 -0,09% 3,18% 54.700
23/07/2018 11,41 11,80 11,35 11,55 +0,79% 3,94% 39.900
20/07/2018 12,09 12,09 11,36 11,46 -5,21% 6,08% 42.500
19/07/2018 11,44 12,26 11,25 12,09 +5,68% 8,83% 69.300
18/07/2018 11,16 11,52 10,83 11,44 +2,88% 6,18% 49.800
17/07/2018 11,72 11,90 11,10 11,12 -4,88% 6,87% 45.300
16/07/2018 12,20 12,30 11,59 11,69 -4,34% 5,82% 78.500
13/07/2018 12,15 12,37 12,10 12,22 +0,91% 2,22% 38.300
12/07/2018 12,48 12,51 12,02 12,11 -2,89% 4,00% 66.500
11/07/2018 12,44 12,63 12,35 12,47 -0,32% 2,25% 38.400
10/07/2018 12,55 12,58 12,26 12,51 -0,95% 2,55% 80.000
09/07/2018 13,11 13,14 12,48 12,63 -2,40% 5,03% 69.400
06/07/2018 12,58 13,15 12,58 12,94 +2,78% 4,53% 70.100
05/07/2018 12,85 12,85 12,12 12,59 -1,25% 5,68% 96.700
03/07/2018 12,55 13,07 12,52 12,75 +1,84% 4,38% 74.900
02/07/2018 12,20 12,63 12,06 12,52 +2,29% 4,67% 145.600
29/06/2018 13,07 13,68 12,21 12,24 -5,48% 11,21% 151.400
28/06/2018 12,99 13,49 12,77 12,95 +0,78% 5,54% 170.400
27/06/2018 14,25 14,40 11,73 12,85 -9,63% 18,74% 344.200